ArticleCancer medicine2025

Efficacy of Almonertinib Versus Osimertinib as the First-Line Treatment for Non-Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study.

Xiujing Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.